Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement
Ainos (NASDAQ:AIMD), a healthcare company specializing in AI-driven point-of-care testing and low-dose interferon therapeutics, has announced its participation in the Webull Corporate Connect Service (CCS). This strategic move aims to enhance investor engagement and transparency through real-time communication with shareholders.
Through the CCS platform, Ainos will showcase corporate milestones, strategic initiatives, and financial results to the investment community. The company's Chairman and CEO, Chun-Hsien Tsai, emphasized that this integration aligns with their commitment to transparent investor communication and will help drive long-term shareholder value.
Ainos (NASDAQ:AIMD), un'azienda sanitaria specializzata in test al punto di cura basati su intelligenza artificiale e terapie con interferone a basse dosi, ha annunciato la sua partecipazione al Webull Corporate Connect Service (CCS). Questa mossa strategica mira a migliorare il coinvolgimento degli investitori e la trasparenza attraverso comunicazioni in tempo reale con gli azionisti.
Attraverso la piattaforma CCS, Ainos presenterà traguardi aziendali, iniziative strategiche e risultati finanziari alla comunità degli investitori. Il presidente e CEO dell'azienda, Chun-Hsien Tsai, ha sottolineato che questa integrazione si allinea con il loro impegno per una comunicazione trasparente con gli investitori e contribuirà a garantire un valore duraturo per gli azionisti.
Ainos (NASDAQ:AIMD), una empresa de salud especializada en pruebas en el punto de atención impulsadas por IA y terapias con interferón en dosis bajas, ha anunciado su participación en el Webull Corporate Connect Service (CCS). Este movimiento estratégico tiene como objetivo mejorar el compromiso de los inversores y la transparencia a través de la comunicación en tiempo real con los accionistas.
A través de la plataforma CCS, Ainos presentará hitos corporativos, iniciativas estratégicas y resultados financieros a la comunidad inversora. El presidente y CEO de la empresa, Chun-Hsien Tsai, enfatizó que esta integración está en línea con su compromiso de comunicación transparente con los inversores y ayudará a impulsar el valor a largo plazo para los accionistas.
Ainos (NASDAQ:AIMD), AI 기반의 현장 검사와 저용량 인터페론 치료를 전문으로 하는 헬스케어 회사가 Webull Corporate Connect Service (CCS)에 참여한다고 발표했습니다. 이 전략적 결정은 주주와의 실시간 소통을 통해 투자자 참여와 투명성을 높이는 것을 목표로 하고 있습니다.
CCS 플랫폼을 통해 Ainos는 투자자 커뮤니티에 기업 이정표, 전략적 이니셔티브 및 재무 결과를 소개할 것입니다. 회사의 회장 겸 CEO인 Chun-Hsien Tsai는 이 통합이 투명한 투자자 소통에 대한 그들의 약속과 일치하며, 장기적인 주주 가치를 추진하는 데 도움이 될 것이라고 강조했습니다.
Ainos (NASDAQ:AIMD), une entreprise de santé spécialisée dans les tests au point de soin alimentés par l'IA et les thérapies à base d'interféron à faible dose, a annoncé sa participation au Webull Corporate Connect Service (CCS). Ce mouvement stratégique vise à améliorer l'engagement des investisseurs et la transparence grâce à une communication en temps réel avec les actionnaires.
Grâce à la plateforme CCS, Ainos présentera des jalons d'entreprise, des initiatives stratégiques et des résultats financiers à la communauté d'investissement. Le président et CEO de l'entreprise, Chun-Hsien Tsai, a souligné que cette intégration est conforme à leur engagement en matière de communication transparente avec les investisseurs et contribuera à créer de la valeur à long terme pour les actionnaires.
Ainos (NASDAQ:AIMD), ein Gesundheitsunternehmen, das auf KI-gesteuerte Punkt-der-Pflege-Tests und niedrig dosierte Interferontherapeutika spezialisiert ist, hat seine Teilnahme am Webull Corporate Connect Service (CCS) bekannt gegeben. Dieser strategische Schritt zielt darauf ab, die Investoreneinbindung und Transparenz durch Echtzeitkommunikation mit den Aktionären zu verbessern.
Über die CCS-Plattform wird Ainos Unternehmensmeilensteine, strategische Initiativen und finanzielle Ergebnisse der Investment-Community präsentieren. Der Vorsitzende und CEO des Unternehmens, Chun-Hsien Tsai, betonte, dass diese Integration mit ihrem Engagement für transparente Investorenkommunikation übereinstimmt und dazu beitragen wird, den langfristigen Aktionärswert zu steigern.
- Enhanced investor visibility through integration with Webull's extensive retail investor platform
- Improved shareholder communication capabilities through real-time digital platform
- None.
SAN DIEGO, CA / ACCESSWIRE / December 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced its participation in the Webull Corporate Connect Service (CCS). This initiative aims to further expand the Company's investor outreach and enhance transparency with its growing shareholder base.
By joining the Webull Corporate Connect Service, Ainos gains access to a dynamic digital platform that facilitates real-time communication with shareholders and retail investors. The Ainos page on CCS will showcase the Company's corporate milestones, strategic initiatives, and financial results directly to a highly engaged investment community, further increasing visibility among retail investors as well as broadening shareholder engagement.
Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "Joining the Webull Corporate Connect Service Platform aligns with our commitment to fostering transparent and meaningful engagement with the investment community. This platform is an efficient method for sharing our business developments, financial updates, and long-term growth strategy with both current and potential investors. We look forward to leveraging Webull's expansive network to enhance our corporate visibility and drive long-term value for our shareholders."
Webull users can stay informed about Ainos' latest updates by following Ainos' page on the Webull CCS platform. To download the app and register for your free Webull account, visit: https://www.webull.com/introduce. Others can access the Company's information on Webull: https://www.webullapp.com/ticker/nasdaq-aimd.
About Ainos, Inc.
Headquartered in San Diego, California, Ainos is a diversified healthcare company focused on novel AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics (VELDONA®). The Company's clinical-stage product pipeline includes VELDONA® human and animal oral therapeutics, human orphan drugs, and telehealth-friendly POCT solutions powered by its AI Nose technology platform. The name "Ainos" is a combination of "AI" and "Nose" to reflect the Company's commitment to empowering individuals to manage their health more effectively with next-generation AI-driven POCT solutions. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Safe Harbor Statement
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "approximate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements.
Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the products announced in this press release; the Company's dependence on projected revenues from the sale of current or future products; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos' product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the accuracy of third-party market research data, the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; continued listing on and compliance with the applicable regulations of the Nasdaq Capital Market; and the Company's success in managing growth. A more complete description of these risk factors and others is included in the "Risk Factors" section of Ainos' Annual Report on Form 10-K for the year ended December 31, 2023, and other public filings with the U.S. Securities and Exchange Commission ("SEC"), many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's filings with the SEC, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release.
The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Any forward-looking statements contained in this press release represent Ainos' views only as of today and should not be relied upon as representing its views as of any subsequent date. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.
Contact Information
Feifei Shen
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on accesswire.com
FAQ
What is the purpose of Ainos (AIMD) joining Webull Corporate Connect Service?
How can investors access Ainos (AIMD) information on Webull?
What benefits will AIMD shareholders get from the Webull Corporate Connect Service?
What services does Ainos (AIMD) specialize in as a healthcare company?
